. AT 1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol Heart Circ Physiol 282: H1206-H1215, 2002; 10.1152/ajpheart.00839.2000.-We assessed ANG II type 1 (AT 1) and type 2 (AT2) receptor (R) expression and functional recovery after ischemia-reperfusion with or without AT1R/AT2R blockade in isolated working rat hearts. Groups of six hearts were subjected to global ischemia (30 min) followed by reperfusion (30 min) and exposed to no drug and no ischemia-reperfusion (control), ischemia-reperfusion and no drug, and ischemia-reperfusion with losartan (an AT 1R antagonist; 1 mol/l), PD-123319 (an AT 2R antagonist; 0.3 mol/l), N 6 -cyclohexyladenosine (CHA, a cardioprotective adenosine A1 receptor agonist; 0.5 mol/l as positive control), enalaprilat (an ANG-converting enzyme inhibitor; 1 mol/l), PD-123319 ϩ losartan, ANG II (1 nmol/l), or ANG II ϩ losartan. Compared with controls, ischemia-reperfusion decreased AT 2R protein (Western immunoblots) and mRNA (Northern immunoblots, RT-PCR) and impaired functional recovery. PD-123319 increased AT 2R protein and mRNA and improved functional recovery. Losartan increased AT 1R mRNA (but not AT1R/AT2R protein) and impaired recovery. Other groups (except CHA) did not improve recovery. The results suggest that, in isolated working hearts, AT 2R plays a significant role in ischemia-reperfusion and AT2R blockade induces increased AT2R protein and cardioprotection.
second strategy is to directly reduce ANG II receptor stimulation by using selective AT 1 R or AT 2 R antagonists. In the nonworking rat heart, pretreatment (1 wk before ischemia) with the AT 1 R antagonist TCV-116 reduced reperfusion injury and improved function (43) . In the same model, acute treatment (from the onset of ischemia) with the AT 1 R antagonist losartan attenuated the postischemic mechanical dysfunction (40) and pretreatment (4-6 h before ischemia) with losartan blocked the increase in AT 1 R binding but did not affect AT 1 R protein or mRNA after ischemia-reperfusion (41) . In the isolated working rat heart (19), we previously showed that the AT 2 R antagonist PD-123319 enhanced (7), whereas losartan worsened (7, 8) , functional recovery after ischemia-reperfusion. We hypothesized that during ischemia-reperfusion in working hearts, AT 2 R is downregulated and AT 2 R blockade induces AT 2 R upregulation and cardioprotection.
The purpose of this study was to determine whether changes in AT 1 R/AT 2 R expression might be related to the recovery of mechanical function after ischemiareperfusion with or without AT 1 R/AT 2 R blockade (with losartan and PD-123319, respectively) in isolated working rat hearts. To gain insight into functional mechanisms, we also determined changes in AT 1 R/ AT 2 R expression and mechanical function with 1) the adenosine A 1 receptor agonist N 6 -cyclohexyladenosine (CHA), to serve as a positive control that is known to improve functional recovery independent of the RAS or ANG II (7), 2) the ACE inhibitor enalaprilat, to decrease endogenous ANG II formation, 3) the combination of losartan and PD-123319, to block both AT 1 Rs and AT 2 Rs and unmask AT 1 R-AT 2 R interaction, 4) ANG II as agonist, to enhance AT 1 R and AT 2 R stimulation, and 5) the combination of ANG II and losartan, to enhance agonist effects on AT 2 R.
METHODS
Experimental animals and isolated working rat heart preparation. All rats were housed and treated according to the guidelines of the Canadian Council on Animal Care and the American Physiological Society. As described previously (7, 8) , male Sprague-Dawley rats (250-300 g), which had been acclimatized and fed ad libitum, were anesthetized with intraperitoneal pentobarbital sodium (50 mg/kg). Hearts were rapidly excised and placed in ice-cooled Krebs-Henseleit solution (pH 7.4, gassed with 95% O 2-5% CO2). Initial Langendorff perfusion of the aorta and coronary arteries was performed with Krebs-Henseleit solution. The pulmonary artery and left atrium were cannulated. After 10 min of Langendorff perfusion, the hearts were switched to working mode by clamping the aortic line and opening the left atrial line. The working hearts were perfused in a closed recirculating system at 37°C in contact with a 95% O 2-5% CO2 mixture. Atrial pacing (300 beats/min) was applied during aerobic perfusion. The perfusate (100 ml) was a modified Krebs-Henseleit solution containing 2.5 mmol/l CaCl 2, 11 mmol/l glucose, 1.2 mmol/l palmitate prebound to 3% BSA (fraction V), and 100 mU/l insulin. Perfusions were made at constant left atrial preload (11.5 mmHg) and afterload hydrostatic pressure (80 mmHg). Heart rate and aortic systolic and diastolic pressures were recorded (P23 Db; Gould). Cardiac output and aortic flow were measured (Transonic T206). Coronary flow, left ventricular (LV) minute work (J), myocardial oxygen consumption (MV O2, mol ⅐ min Ϫ1 ⅐ g dry wt Ϫ1 ), myocardial efficiency (%J), and coronary vascular conductance (CVC, ml ⅐ min Ϫ1 ⅐ mmHg Ϫ1 ) were calculated. Experimental protocol. Hearts were randomly assigned to nine groups of six hearts each: control (no drug, no ischemiareperfusion), ischemia-reperfusion (no drug), and ischemiareperfusion with PD-123319 (0.3 mol/l), CHA (0.5 mol/l as positive control), losartan (1 mol/l), enalaprilat (1 mol/l), PD-123319 (0.3 mol/l) ϩ losartan (1 mol/l), ANG II (1 nmol/l), or ANG II (1 nmol/l) ϩ losartan (1 mol/l). Control hearts were perfused aerobically for 80 min. Hearts in ischemia-reperfusion groups were perfused aerobically in the working mode for 50 min and then subjected to 30 min of global, no-flow ischemia (in the presence or absence of drug) and 30 min of reperfusion. After ischemia, the left atrial inflow was reestablished and pacing (stopped during ischemia) was recommenced after 3 min of reperfusion. The drugs were added to the perfusate 5 min before the onset of ischemia and remained throughout the reperfusion period. To determine whether the drugs modified receptor expression in the absence of ischemia-reperfusion, we studied additional controls with each drug or combination (7 groups) and 80-min aerobic perfusion. At the end of the experiments, LV tissue samples were stored at Ϫ70°C and powdered in liquid nitrogen for analysis of AT1R/AT2R protein and mRNA expression (24, 34) .
Western blot analysis for AT1R and AT2R proteins. Aliquots of powdered LV tissue (10 mg) were sonicated in homogenization solution (2% SDS, 100 mmol/l dithiothreitol, 60 mmol/l Tris, pH 6.8) at 4°C and boiled at 100°C. The boiled homogenate was subjected to PAGE followed by electrotransfer to nitrocellulose. The nitrocellulose membranes were then blocked with 5% (wt/vol) skimmed milk powder in 1ϫ PBS and 0.05% (vol/vol) of Tween 20 at room temperature. For AT1R protein, the nitrocellulose membranes were incubated with affinity-purified rabbit anti-human AT1R antibody (Santa Cruz Biotechnology) at a dilution of 1:2,000 for 2 h at room temperature. The membranes were washed with PBSTween 20 (0.05%; TPBS) three times, followed by incubation with goat anti-rabbit IgG antibody conjugated to peroxidase, and visualized with chemiluminescence detection (ECL Western blot kit, Amersham). Gels with 15 lanes were used. The intensity of bands was quantified by scanning densitometry with standard image analysis software, and images were aligned with the intensity bars for illustrations with the Sigma Gel computer graphics package (SPSS). For AT2R proteins, the same procedure as that for AT 1R was used except that incubation with goat anti-human AT 2R antibody (Santa Cruz Biotechnology) at a dilution of 1:500 was followed by incubation with donkey anti-goat IgG (BioCan Scientific, Mississauga, ON, Canada).
cDNA probe preparation. cDNAs for AT 1aR and AT2R were obtained from the laboratory of Dr. V. Dzau (Harvard Medical School, Boston, MA) and used to prepare probes for analysis of rat AT 1R and AT2R mRNA. Human AT2R and mouse AT 1aR cDNA were subcloned into the plasmid pcDNA3 (13). The plasmid DNA was then digested using two restriction enzymes that flanked the cDNA for the receptors (AT 2R and AT1aR). In both cases, the 1.1-kb cDNA fragments for both receptors were gel purified and 25 ng of each was labeled with [␣-32 P]dCTP (DuPont, Mississauga, ON, Canada) with a random primer method. The labeled probes were separated from unincorporated nucleotides by using Sephadex G-50 spin columns and were used in Northern blot analysis.
Northern blot analysis for AT 1R and AT2R mRNA. Total RNA was extracted from rat LV myocardium with the acid guanidinium-thiocyanate-phenol-chloroform extraction method with TRIzol reagent (Life Technologies, Burlington, ON, Canada). Aliquots (20 g) of total RNA were electrophoretically size-fractionated in a 1% MOPS-3% formaldehyde buffer on a 1% agarose-3% formaldehyde gel. These RNA samples were then transferred to Nytran membrane (Schleicher and Schuell, Keene, NH) and cross-linked under ultraviolet light for 30 s. The membranes were then prehybridized in the solution mixture containing 50% formamide, 5ϫ SSC (sodium chloride-sodium citrate), 5ϫ Denhardt's solution, 0.1% SDS, 0.05 mol/l sodium phosphate buffer (pH 6.8), 0.1% sodium pyrophosphate, and 50 g/ml sheared herring sperm DNA at 42°C for 3 h. The membranes were then hybridized with a 32 P-labeled probe specific for AT1aR and AT2R in the same buffer for 18-24 h at 42°C. Membranes were washed with successively stringent buffers at room temperature in 2ϫ SSC containing 0.1% SDS for 30 min twice, at 1ϫ SSC containing 0.1% SDS for 30 min, and at 55°C in 0.2ϫ SSC containing 0.1% SDS for 45 min. The membranes were exposed to Kodak X-OMAT film (Eastman Kodak, Rochester, NY) with an intensifying screen for 1-2 wk at Ϫ80°C. The autoradiograms were quantified by scanning densitometry with image analysis software (Sigma Gel, SPSS). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to normalize the differences in loaded and transferred mRNA.
RT-PCR assay. Northern blot data were verified with semiquantitative RT-PCR. Total RNA from flash-frozen ventricular tissue was isolated with TRIzol reagent as described by the supplier (Life Technologies). The RNA was ethanol precipitated and reconstituted in distilled, deionized water, and the concentration was determined by measurement of the absorbance at 260 nm. All RNA samples were stored frozen at Ϫ80°C. Poly A ϩ RNA was isolated by Oligotex mRNA Kit (Qiagen; Mississauga, ON, Canada). Purity and RNA integrity were assessed by absorbance at 260/280 nm and by agarose gel electrophoresis.
RT-PCR was done with a two-step protocol for RT-PCR method following the manufacturer's instructions. Conditions for RT-PCR included 1 g of Poly A ϩ RNA and downstream priming with primers AT1a, AT2, and GAPDH in the presence of Ready-To-Go RT-PCR Beads (Amersham Pharmacia Biotech, Piscataway, NJ) at 42°C for 30 min. After denaturation at 95°C for 5 min, PCR was conducted: 95°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min. The cycle numbers were 36 for AT1a and AT2 and 32
for GAPDH. For all PCR reactions, the number of cycles was found to be in the linear range of product accumulation (not shown). A final PCR extension was performed at 72°C for 5 min. PCR amplifications (10, 11) were done for AT 1a, AT2, and GAPDH with the following primers: 1) AT 2 receptor, 5Ј-TTGCTGCCACCAGCAGAAAC-3Ј (the upstream primer is complementary to nucleotides 3070-3089) and 5Ј-GTGT-GGGCCTCCAAACCATTGCTA-3Ј (the downstream primer is complementary to nucleotides 4172-4195); the cDNA amplification product is 1125 bp (10); 2) AT 1a receptor, 5Ј-GCACACTGGCAATGTAATGC-3Ј (the upstream primer is complementary to nucleotides 1370-1389) and 5Ј-GTTGAA-CAGAACAAGTGACC-3Ј (the downstream primer is complementary to nucleotides 1737-1756); the cDNA amplification product is 385 bp (11); and 3) GAPDH, 5Ј-AATGCATCCTG-CACCACCAACTGC-3Ј (the upstream primer is complementary to nucleotides 524-547) and 5Ј-GGAGGCCATGTAGGC-CATGAG-GTC-3Ј (the downstream primer is complementary to nucleotides 1055-1078); the cDNA amplification product is 555 bp. PCR products were analyzed by 1.5% agarose gel electrophoresis with a 1-kbp ladder as size marker. All PCR reactions were done at least three times with different RNA preparations (n ϭ 3) and gave identical results. Photographic images were obtained, digitized, and quantified with Sigma Gel (SPSS).
Protein kinase C and p38 mitogen-activated protein kinase. To determine whether protein kinase C (PKC)-⑀ and p38 mitogen-activated protein kinase (MAPK) are activated during AT 2R antagonism, we measured these proteins by Western blotting as described by Ping et al. (26) and Zhao et al. (45) , respectively. Briefly, the same procedure as for AT 1/ AT 2R proteins was used, except that incubation with rabbit p38 anti-rat polyclonal or phosphorylated p38 mouse monoclonal antibodies (Santa Cruz Biotechnology) were used for p38 and mouse monoclonal anti-rat nPKC-⑀ antibody (1:100 dilution) followed by anti-mouse IgG HRP conjugate (1:2,000 dilution).
cGMP content. To determine whether cGMP [an index of nitric oxide (NO)] is increased during AT 2R antagonism, we measured LV myocardial cGMP content with the commercially available cGMP enzyme immunoassay kit (Amersham Pharmacia Biotechnology, Quebec City, PQ, Canada) and expressed the levels as femtomoles per milligram of wet weight, as described previously (37) .
Statistics. Data are shown as means Ϯ SE. Data were analyzed with ANOVA (with repeated measures followed by a Student t-test with the Bonferroni correction for repeated comparisons) and linear regression analysis. Statistical significance was set at P Ͻ 0.05.
RESULTS

Recovery of function after global ischemia.
For all groups, baseline values of LV work, coronary flow, and cardiac output were essentially similar ( Figs. 1 and 2 ; Table 1 ). In the ischemia-reperfusion (no drug) group, LV work remained significantly depressed during reperfusion, functional recovery being only 51 Ϯ 10% of the preischemic value (Fig. 1A) . Also, coronary flow and cardiac output were both significantly depressed (Table 1 ). In the PD-123319 and CHA groups, recovery of LV work with reperfusion improved to 82 Ϯ 4 and 81 Ϯ 4%, respectively (P Ͻ 0.001 vs. ischemia-reperfusion, no drug; Fig. 1A ). Coronary flow and cardiac output were also enhanced in those groups (Table 1 ). In contrast, the losartan group did not show any recovery of LV work (P Ͻ 0.0001 vs. ischemia-reperfusion, no drug), and coronary flow and cardiac output were further impaired compared with the PD-123319 and CHA groups ( Table 1 ). The recovery of LV work with reperfusion in the ANG II or ANG II ϩ losartan (Fig. 1B) , enalaprilat ( Fig. 2A) , or PD-123319 ϩ losartan (Fig.  2B ) groups did not differ from that in the ischemiareperfusion (no drug) group and exceeded that in the losartan group. The effects on coronary flow and cardiac output among the groups were concordant with the effects on LV work (Table 1) . Compared with the ischemia-reperfusion group, losartan decreased peak systolic pressure, cardiac output, MV O 2 , LV work, coronary flow, and myocardial efficiency. In contrast, PD-123319 and CHA improved peak systolic pressure, cardiac output, and LV work. Despite changes in flow, CVC did not change (Table 1) .
AT 1 R and AT 2 R proteins. The Western blot gels for rat hearts displayed a major band for AT 1 six hearts (Fig. 3A) . In contrast, AT 2 R protein expression for hearts in the nine groups showed quantitative differences among the groups (Fig. 3B) , with significant increase in AT 2 R protein with ischemia-reperfusion ϩ PD-123319 or ischemia-reperfusion ϩ PD-123319 ϩ losartan compared with control (P Ͻ 0.007-0.001) and ischemia-reperfusion (no drug) (P Ͻ 0.007-0.001). Also, AT 2 R protein expression was less (P Ͻ 0.02) than control with ischemia-reperfusion (no drug) or ischemia-reperfusion combined with losartan, ANG II, or ANG II ϩ losartan. Compared with ischemia-reperfusion (no drug), enalaprilat increased AT 2 R pro- Values are means ϩ SE; n ϭ 6 in all groups. B, baseline; R, reperfusion; Los, losartan; LosϩANG II, losartan ϩ ANG II, PD, PD-123␤19; CHA, N 6 -cyclohexyladenosine; En, enalaprilat; CF, coronary flow; CO, cardiac output; CVC, coronary vascular conductance; IR, ischemiareperfusion; LV, left ventricular; MV O2, myocardial oxygen consumption; PSP, peak systolic pressure. * P Ͻ 0.05 vs. IR. tein (P ϭ 0.001). Within the ischemia-reperfusion (no drug) and ischemia-reperfusion ϩ PD-123319 groups, significant positive correlations (linear regression analysis) were found between recovery of LV work (%) and AT 2 R protein levels (r ϭ 0.94, P ϭ 0.002 and r ϭ 0.99, P ϭ 0.0002, respectively) and negative correlations between recovery of LV work and the narrow range of AT 1 R protein levels (r ϭ Ϫ0.95, P ϭ 0.003 and r ϭ Ϫ0.96, P ϭ 0.003, respectively).
AT 1 R and AT 2 R mRNAs. RT-PCR (3 blots scanned) confirmed results obtained by Northern blots (6 blots scanned; not shown). Compared with control and ischemia-reperfusion alone, there was a marked increase in AT 1 R mRNA intensity with ischemia-reperfusion ϩ losartan (P Ͻ 0.001) and a lesser increase with ischemia-reperfusion ϩ PD-123319 ϩ losartan (P Ͻ 0.001) on RT-PCR (Fig. 4A) . Both PD-123319 and ANG II prevented the losartan-induced increase in AT 1 R mRNA. Compared with control, AT 1 R mRNA decreased with ischemia-reperfusion alone (P ϭ 0.03) and ischemia-reperfusion combined with ANG II (P ϭ 0.03) or ANG II ϩ losartan (P ϭ 0.03). Compared with control or ischemia-reperfusion alone, AT 2 R mRNA intensity on RT-PCR (Fig. 4B) increased markedly with ischemia-reperfusion ϩ PD-123319 (P Ͻ 0.001) and to a lesser extent with ischemia-reperfusion ϩ PD-123319 ϩ losartan (P Ͻ 0.04-0.001). Importantly, losartan prevented the PD-123319-induced increase in AT 2 R mRNA. Compared with control, AT 2 R mRNA decreased with ischemia-reperfusion alone (P ϭ 0.01) and ischemia-reperfusion combined with losartan (P ϭ 0.04), ANG II (P ϭ 0.02), or ANG II ϩ losartan (P ϭ 0.03). Compared with ischemia-reperfusion alone, enalaprilat increased AT 2 R mRNA (P ϭ 0.004).
Effect of treatments during aerobic perfusion. The aerobic "controls" did not show significant differences in any of the parameters, including LV work (Fig. 5) , AT 1 R/AT 2 R protein (Fig. 6 ), or AT 1 R/AT 2 R mRNA (Fig. 7) .
Effect on cGMP. Compared with control, LV cGMP content showed a significant decrease with ischemiareperfusion alone (2.65 Ϯ 0.10 vs. 1.56 Ϯ 0.18 fmol/mg wet wt; P Ͻ 0.002) and a significant increase with ischemia-reperfusion ϩ PD-123319 (2.65 Ϯ 0.10 vs. 3.26 Ϯ 0.20 fmol/mg wet wt; P Ͻ 0.05) (Fig. 8A) .
Effect on PKC-⑀ and p38 MAPK. Compared with control, phosphorylated p38 (p-p38; Fig. 8B ) and the ratio of p-p38 to p38 (not shown) were significantly increased (P Ͻ 0.05) with ischemia-reperfusion alone or combined with PD-123319. Compared with control or ischemia-reperfusion alone (Fig. 8, C and D) , signif- icant increases (1.3-fold; P Ͻ 0.05) were found in both membrane PKC-⑀ and total cytosolic PKC-⑀.
DISCUSSION
There are two major new findings in this study. First, acute ischemia-reperfusion in isolated working rat hearts induced decreased AT 2 R protein expression and impaired recovery of mechanical function. Second, acute AT 2 R blockade produced selective increase in AT 2 R protein and improved recovery of function. The findings suggest that AT 2 R plays a significant role in ischemia-reperfusion and that AT 2 R blockade induces increased AT 2 R protein and cardioprotection. Although we are aware that expression does not lead to activation unless endogenous agonist is present, we have inferred that increase in AT 2 R protein expression may lead to increase in AT 2 R activation. We have provided indirect evidence suggesting that AT 2 R activation follows AT 2 R expression. Thus, after ischemia-reperfusion, AT 2 R was downregulated and correlated with decreased cardiac function, and both these effects on AT 2 R expression and cardiac function were reversed by the AT 2 R blocker PD-123319. In addition, our preliminary data suggest that p38, PKC-⑀, and cGMP were affected by AT 2 R blockade, providing further evidence that AT 2 R activation was taking place.
Mechanisms. The molecular and functional changes in response to ischemia-reperfusion and the selected drug treatments in this study provide important insights into AT 1 R/AT 2 R functions during cardioprotection. First, the AT 2 R antagonist may act on myocardium, via AT 2 R found on cardiomyocytes (35) , to enhance recovery of LV function. Our finding that PD-123319 induced selective enhancement of both the AT 2 R message and its protein in LV myocardium after ischemia-reperfusion, with no effect on AT 1 R mRNA or protein, provides clear evidence for the effect of the selective blocker on AT 2 Rs and is indicative of the specificity of action of PD-123319 in eliciting the protective effect. PD-123319 is a known selective AT 2 R antagonist (with no partial agonist activity) that is widely used to characterize AT 2 R-mediated mechanisms (5) . The responses in this study were not mediated by an indirect effect on the coronary circulation because there was no significant change in CVC with PD-123319 or losartan. In agreement with Yoshiyama et al. (42) , exogenous ANG II did not affect flow, CVC, or recovery of function.
Second, AT 2 R blockade might have improved the balance between AT 1 R and AT 2 R stimulation. Although AT 1 R blockade upregulates the RAS and exposes AT 2 Rs to increased ANG II levels in vivo (14), the isolated heart in vitro is not exposed to elevated circulating ANG II. However, local ANG II is increased after ischemia-reperfusion (44) . In this study, ANG II alone or combined with an AT 1 R blocker did not improve recovery of function after ischemia-reperfusion, although exogenous ANG II decreased AT 1 R mRNA and overcame the myocardial depressant effect of the blocker. Exogenous ANG II also decreased AT 2 R mRNA and protein after ischemia-reperfusion and induced further decrease when combined with the AT 1 R blocker. Although postischemic recovery of LV function was similar with the combination of AT 1 R and AT 2 R blockade compared with ANG II, ANG II ϩ AT 1 R blockade, ACE inhibition, or ischemia-reperfusion alone, the combination 1) overcame the myocardial depressant effect seen with the AT 1 R blocker alone and 2) increased AT 2 R protein (and AT 1 R/AT 2 R mRNA) compared with both control and ischemia-reperfusion groups. In support of these findings, AT 2 R stimulation was recently shown to inhibit responses to AT 1 R activation (20) .
Third, the effects of the AT 1 R/AT 2 R blockers during ischemia-reperfusion might involve AT 1 R and AT 2 R interaction or cross talk at the mRNA level. Although we did not confirm cross talk in cell culture, AT 1 R blockade during ischemia-reperfusion caused selective increase in AT 1 R mRNA and decrease in AT 2 R mRNA. In combination, the AT 1 R blocker inhibited the increase in AT 2 R mRNA and recovery of LV function induced by AT 2 R blockade, and the AT 2 R blocker inhibited the increase in AT 1 R mRNA and deterioration of function induced by AT 1 R blockade.
Fourth, our finding that the adenosine A 1 agonist CHA enhances recovery of function without altering AT 1 R or AT 2 R mRNA corroborates the view that its beneficial effect does not involve the RAS (7). This finding, together with the association of AT 2 R upregulation and enhanced function with PD-123319 and increased AT 1 R mRNA and worsened function with losartan, supports the idea that increased mRNA per se might not be causally related to enhanced functional recovery.
Fifth, our finding of decreased AT 1 R/AT 2 R mRNA during ischemia-reperfusion is consistent with increased endogenous ANG II production in working rat hearts. Although no change was seen in AT 1 R protein during ischemia-reperfusion, AT 2 R protein decreased by nearly 40% (Fig. 3) . This was associated with decrease in mRNA by nearly 50% for AT 1 R and 60% for AT 2 R compared with control (Fig. 4) . Because these decreases in response to 30 min of ischemia are fairly substantial, they cannot simply be ascribed to cellular damage because 1) they were prevented by the ACE inhibitor enalaprilat (which by itself did not enhance functional recovery) and 2) treatments with the specific AT 1 R/AT 2 R blockers had opposing effects on mRNAs and functional recovery. Although enalaprilat (which decreases endogenous ANG II formation) did not enhance functional recovery compared with ischemiareperfusion alone, recovery with enalaprilat was greater than with AT 1 R blockade and enalaprilat induced preservation of AT 2 R mRNA and protein as well as AT 1 R mRNA during ischemia-reperfusion. Rapid changes in expression of mRNA and/or protein for a variety of proteins involved in cell signaling have recently been reported (1-4, 23, 25, 39) , including AT 1 R (41).
Sixth, the receptor changes after ischemia-reperfusion in our study are consistent with the pharmacolog- ical principle that agonists produce receptor downregulation whereas antagonists produce upregulation. The lack of increase in AT 1 R protein with AT 1 R blockade and ischemia-reperfusion was probably because the short exposure time was insufficient to increase AT 1 R protein synthesis (or because protein degradation was enhanced). Similarly, the increase in AT 1 R mRNA could be due to enhanced synthesis (or increased halflife). Because increased AT 2 R protein levels followed increased AT 2 R mRNA expression after similar durations of exposure to AT 2 R blockade and ischemia-reperfusion, it is possible that the rate of translation might be higher for AT 2 R than for AT 1 R. Although AT 1 Rs are internalized and recycled, this does not seem to be the case with AT 2 Rs (13).
Potential role of AT 2 R blockade in cardioprotection. There are very few data on AT 2 R or its blockade because AT 2 R was considered to be in low abundance, without significant functional consequences (28) . The two distinct subtypes of ANG II receptors were identified on the basis of their inhibition by highly specific and selective nonpeptide ANG II receptor ligands, losartan for AT 1 R and PD-123319 for AT 2 R (6, 29). Early studies indicated that AT 1 Rs are dominant in adult tissues, whereas AT 2 Rs are abundant in fetal tissues, and most of the physiological actions of ANG II are normally mediated through the AT 1 R. However, the profile of AT 1 R and AT 2 R expression depends on the type of cardiac tissue, the type of preparation, the cell type, and the pathological condition (21) . Although AT 1 Rs and AT 2 Rs are found in equal proportion in rat myocardium, AT 2 Rs are dominant in human myocardium, the ratio of AT 2 R to AT 1 R being 2:1 (28). AT 2 Rs, recently reviewed by Horiuchi et al. (14) , are reexpressed or upregulated in cardiac hypertrophy, myocardial infarction, and heart failure, whereas AT 1 Rs are downregulated in heart failure (12) . After myocardial infarction in the rat in vivo, AT 1 R and AT 2 R mRNA increase and peak at 24 h (46). Thus AT 2 Rs participate in the pathophysiology of disease in adult hearts. Our findings suggest that AT 2 Rs play a significant role in acute ischemia-reperfusion in working rat hearts and that the cardioprotective effect of acute AT 2 R blockade is associated with increased AT 2 R protein expression.
Other studies. There are no other reports comparing effects of acute AT 1 R/AT 2 R blockade, ACE inhibition, and ANG II on AT 2 R mRNA or protein after ischemiareperfusion in adult rat hearts in vitro. In contrast, there are many reports involving AT 1 R blockade. In nonworking rat hearts, LV function improved gradually and modestly after ischemia-reperfusion with both acute losartan (40) and chronic losartan pretreatment (41) , and losartan did not affect AT 1 R mRNA or protein after ischemia-reperfusion but decreased AT 1 R binding (41) . Others found that pretreatment with 1) ANG II augments reperfusion injury independent of a vasocontrictive effect (42, 43) , 2) losartan improves recovery of LV function after ischemia-reperfusion (36) , and 3) TCV-116 is cardioprotective to ischemia-reperfusion and decreased ANG II (43) . In a pig model of in vivo ischemia-reperfusion, 30-min pretreatment with the AT 1 R blocker candesartan decreased infarct size, whereas PD-123319 produced a slight nonsignificant decrease (17% vs. 22%) compared with placebo (16) . The reason for the discrepancy is not clear, but it may be related to the greater hemodynamic load and metabolic demand in isolated working vs. nonworking hearts (19) . In addition, the time window during which treatment is applied might be important. Thus pretreatment could modify receptor status and responses to ischemia-reperfusion. Because chronic pretreatment with an AT 1 R antagonist increases plasma and myocardial ANG II (36) , withdrawal before an acute ischemia-reperfusion experiment produces heightened stimulation of AT 1 Rs and AT 2 Rs. In fact, AT 1 R stimulation was shown to be cardioprotective in rabbit hearts (18) . Intrinsic AT 1 R activation may also contribute to functional recovery after AT 2 R blockade (8), possibly via an AT 1 R-mediated positive inotropism.
Although our findings with AT 2 R blockade during acute ischemia-reperfusion in this study and others (7, 8) suggest that acute increase in AT 2 R expression and potential AT 2 R activation might be harmful, this does not necessarily conflict with the postulated beneficial role of the mild-to-modest AT 2 R stimulation during chronic AT 1 R blockade. This concept (16, 17, 33) assumes that during chronic AT 1 R blockade, shunting of ANG II to AT 2 Rs induces AT 2 R activation and unopposed AT 2 R effects involving bradykinin, PGs, and NO, but data on AT 2 R protein or mRNA or downstream signaling are needed. Under chronic conditions, AT 2 Rs in coronary endothelial cells exert antigrowth and antiproliferative effects that are offset by the growthpromoting effects of AT 1 R stimulation (28) . AT 2 Rs also mediate apoptosis (38) , so that AT 2 R blockade could inhibit apoptosis. However, in rats with chronic heart failure 2 mo after infarction, a beneficial effect of AT 1 R blockade on LV remodeling was attenuated by chronic AT 2 R blockade with PD-123319 (17) . Several studies have implicated NO and free radicals in the expression of ANG II receptors (15, 31) .
In this study, we found increases in PKC-⑀ and cGMP in the combined ischemia-reperfusion and PD-123319 hearts, suggesting that the protective effect of AT 2 R antagonism might involve signaling through these molecules. Signaling through PKC-⑀ and cGMP has been implicated in ischemic preconditioning (26) . Although the p38 MAPK pathway has been implicated in adenosine-induced ischemic preconditioning, we did not find an increase in p38 in the combined ischemiareperfusion and CHA group, but p38 increased significantly in the PD-123319 group. We did not find a consistent correlation between the activity of p38, PKC-⑀, or cGMP and functional recovery or expression of AT 1 R/ AT 2 Rs in the other ischemia-reperfusion groups.
As reviewed by Jalowy et al. (16) , AT 1 R blockade is not universally beneficial in all models of ischemiareperfusion in all species (7, 8) or in other models (22, 30, 32) , as is often assumed (9, 16, 17, 40, 41) . Although the beneficial effects of long-term AT 1 R blockade after infarction (9) support the role of AT 1 R during cardiac remodeling after infarction, AT 2 Rs are likely involved (12, 20, 38) . Whether AT 2 R blockade might be beneficial in vivo during more prolonged acute ischemiareperfusion or recurrent ischemic episodes after infarction requires further study. Further studies are also needed to define the pathways involved.
In conclusion, in the isolated working rat heart, 1) decreased AT 2 R protein is associated with impaired recovery of mechanical function after acute ischemiareperfusion and 2) increased AT 2 R protein after acute AT 2 R blockade is associated with enhanced recovery, suggesting a potential link between increased AT 2 R protein expression and cardioprotection.
